Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Enoxaparin · Enoxaparin Sodium, Lovenox

Other · developed by Sanofi Aventis Us

Approved FDA, Mar 1993
3 Registered trials

What is Enoxaparin?

Enoxaparin is a low molecular weight heparin, a synthetic anticoagulant that acts with a higher ratio of anti-Factor Xa to anti-Factor IIa activity. It is studied in venous thromboembolism, deep venous thrombosis, pulmonary embolism and metastatic pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Enoxaparin Sodium, Lovenox, Clexane, Inhixa
Drug type
Other
Pathways
anticoagulation, anti-Factor Xa activity, anti-Factor IIa activity
Therapy area
Cardiovascular, Oncology
Developer
Sanofi Aventis Us
In trials of
ASPE, HALO, REGN
FDA status
Approved as Enoxaparin Sodium, Lovenox (March 29, 1993), NDA020164 · FDA label
UNII
E47C0NF7LV

✅ FDA-approved uses

From the indications section of the FDA label (version of May 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01828697 Phase 4 Deep Venous Thrombosis Completed ASPE
NCT07015905 Phase 3 Venous Thromboembolism (VTE) Recruiting REGN
NCT01839487 Phase 2 Metastatic Pancreatic Cancer Completed HALO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Venous Thromboembolism (VTE)Deep Venous ThrombosisMetastatic Pancreatic CancerPulmonary Embolism

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.